{
    "nctId": "NCT05181202",
    "briefTitle": "Biomarkers of Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients",
    "officialTitle": "Biomarkers Study of Liposomal Doxorubicin Injection Induced Hypersensitivity Reaction in Breast Cancer Patients",
    "overallStatus": "UNKNOWN",
    "conditions": "Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "The predictive biomarkers of PLD induced hypersensitivity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* \u226518 years old; Breast cancer confirmed with histological or molecular diagnosis; Advanced breast cancer diagnosis according to American Joint Committee on cancer eighth edition cancer staging manual; Treatment with liposomal doxorubicin; No pregnancy plan and voluntary use of effective contraceptive measures during treatment\n\nExclusion Criteria:\n\n* Subjects who discontinued treatment due to previous severe adverse reactions to liposomal doxorubicin or doxorubicin; poor compliance.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}